{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:44:30Z","timestamp":1787312670305,"version":"build-2736575974"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"AstraZeneca Pharmaceuticals LP"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ejps.2019.105061","type":"journal-article","created":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T01:52:43Z","timestamp":1567216363000},"page":"105061","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modelling"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9147-9357","authenticated-orcid":false,"given":"Li","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Rowland","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Higashimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidal","family":"Al-Huniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diansong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2019.105061_bb0005","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10928-015-9457-6","article-title":"A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation","volume":"43","author":"Akil","year":"2016","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2019.105061_bb0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1389200023338017","article-title":"Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update","volume":"3","author":"Alex","year":"2002","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2019.105061_bb0015","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/cpt.719","article-title":"Pharmacometric modeling of naloxegol efficacy and safety: impact on dose and label","volume":"102","author":"Al-Huniti","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105061_bb9005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00008571-199202000-00005","article-title":"Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects","volume":"2","author":"Andersson","year":"1992","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ejps.2019.105061_bb0020","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1046\/j.1365-2125.1998.t01-1-00702.x","article-title":"Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole","volume":"45","author":"Andersson","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb0025","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40262-013-0089-y","article-title":"Differences in cytochrome P450-mediated pharmacokinetics between Chinese and Caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling","volume":"52","author":"Barter","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2019.105061_bb9010","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0009-9236(97)90116-8","article-title":"Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizersof S-mephenytoin","volume":"62","author":"B\u00f6ttiger","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105061_bb0030","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/jcph.693","article-title":"Effects of CYP3A modulators on the pharmacokinetics of naloxegol","volume":"56","author":"Bui","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb9015","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/0091270009333016","article-title":"Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms","volume":"49","author":"Chen","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb0035","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1128\/AAC.00423-11","article-title":"Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use","volume":"55","author":"Damle","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2019.105061_bb0040","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","article-title":"Clinical significance of the cytochrome P450 2C19 genetic polymorphism","volume":"41","author":"Desta","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2019.105061_bb0045","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00228-015-1834-y","article-title":"Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway","volume":"71","author":"Feng","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb0050","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejphar.2009.10.007","article-title":"Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram","volume":"626","author":"Fudio","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb9020","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0009-9236(99)70034-2","article-title":"Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans","volume":"66","author":"Furuta","year":"1999","journal-title":"Clinical Pharmacology & Therapeutics."},{"key":"10.1016\/j.ejps.2019.105061_bb0055","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1093\/jac\/dkt229","article-title":"Steady-state pharmacokinetics and metabolism of voriconazole in patients","volume":"68","author":"Geist","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2019.105061_bb9025","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00228-005-0063-1","article-title":"Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype","volume":"62","author":"Hai-Ling","year":"2006","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb0060","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/bcp.12884","article-title":"Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians","volume":"81","author":"Hasunuma","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb0065","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1365-2125.2003.01874.x","article-title":"Metabolism of citalopram enantiomers in CYP2C19\/CYP2D6 phenotyped panels of healthy Swedes","volume":"56","author":"Herrlin","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb0070","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1111\/bcp.13297","article-title":"Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics","volume":"83","author":"Hohmann","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb0075","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0149-2918(00)80032-6","article-title":"The proton-pump inhibitors: similarities and differences","volume":"22","author":"Horn","year":"2000","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejps.2019.105061_bb0080","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.31.5.540","article-title":"Identification of the cytochrome P450 enzymes involved in the oxidation of voriconazole","volume":"31","author":"Hyland","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.105061_bb0085","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s002280100342","article-title":"Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism","volume":"57","author":"Ieiri","year":"2001","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb9030","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/01213011-200512000-00003","article-title":"Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status","volume":"15","author":"Ieiri","year":"2005","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.ejps.2019.105061_bb0090","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.clpt.2004.02.002","article-title":"Pharmacokinetics of voriconazole and cytochrome p450 2C19 genetic status","volume":"75","author":"Ikeda","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105061_bb0095","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00008571-199704000-00003","article-title":"Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4\u2032-hydroxylation activities in livers of Japanese and Caucasian populations","volume":"7","author":"Inoue","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ejps.2019.105061_bb0100","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/AAC.01123-08","article-title":"Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A","volume":"53","author":"Jeong","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2019.105061_bb0105","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/bdd.1899","article-title":"Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents","volume":"35","author":"Johnson","year":"2014","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2019.105061_bb9035","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1046\/j.1365-2125.2002.01366.x","article-title":"Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19","volume":"53","author":"Joo-Youn","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb0110","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1067\/mcp.2002.126176","article-title":"Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19","volume":"72","author":"Kim","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105061_bb0115","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/03639040802220284","article-title":"Acido-basic properties of proton pump inhibitors in aqueous solutions","volume":"35","author":"Kristl","year":"2009","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2019.105061_bb9040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00228-005-0063-1","article-title":"Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype","volume":"62","author":"Lan","year":"2006","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb0120","doi-asserted-by":"crossref","first-page":"458","DOI":"10.2165\/00003088-199528060-00004","article-title":"Clinical pharmacokinetics of lansoprazole","volume":"28","author":"Landes","year":"1995","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2019.105061_bb0125","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/0091270010395510","article-title":"Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers","volume":"52","author":"Lee","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb9045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s13318-013-0148-7","article-title":"A correlative study of polymorphisms of CYP2C19 and MDR1 C3435T with the pharmacokinetic profiles of lansoprazole and its main metabolites following single oral administration in healthy adult Chinese subjects","volume":"39","author":"Li","year":"2014","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2019.105061_bb9050","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00228-008-0608-1","article-title":"Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes","volume":"65","author":"Li-Jun","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb0130","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2125.2009.03578.x","article-title":"Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17","volume":"69","author":"Li-Wan-Po","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb0135","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/tpj.2012.10","article-title":"Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes","volume":"13","author":"Martis","year":"2013","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.ejps.2019.105061_bb0140","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1517\/17425255.2012.657626","article-title":"Cytochrome P450 variations in different ethnic populations AU - McGraw, Joseph","volume":"8","author":"McGraw","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejps.2019.105061_bb0145","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.clpt.2006.04.004","article-title":"Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir","volume":"80","author":"Mikus","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105061_bb0150","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/sj.clpt.6100482","article-title":"Pharmacokinetics\/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations","volume":"84","author":"Myrand","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105061_bb9055","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/0049825021000023996","article-title":"Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent","volume":"33","author":"Nan","year":"2003","journal-title":"Xenobiotica."},{"key":"10.1016\/j.ejps.2019.105061_bb0155","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1248\/bpb.28.1805","article-title":"Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes","volume":"28","author":"Niwa","year":"2005","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejps.2019.105061_bb0160","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00228-009-0657-0","article-title":"Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker","volume":"65","author":"Noehr-Jensen","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb0165","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00228-008-0529-z","article-title":"Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects","volume":"64","author":"Ohlsson Rosenborg","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb0170","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000028333","article-title":"Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes","volume":"59","author":"Olesen","year":"1999","journal-title":"Pharmacology"},{"key":"10.1016\/j.ejps.2019.105061_bb9060","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/0091270004265702","article-title":"Omeprazole as a CYP2C19 Marker in Chinese Subjects: Assessment of Its Gene-Dose Effect and Intrasubject Variability","volume":"44","author":"Ophelia","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb9065","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/00008571-200412000-00007","article-title":"Pharmacogenetics and herb\u2013drug interactions: experience with Ginkgo biloba and omeprazole","volume":"14","author":"Ophelia","year":"2004","journal-title":"Pharmacogenetics."},{"key":"10.1016\/j.ejps.2019.105061_bb0175","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0278-5846(82)80181-4","article-title":"Kinetics of citalopram in man; plasma levels in patients","volume":"6","author":"Over\u00f8","year":"1982","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejps.2019.105061_bb0180","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2125.2003.01993.x","article-title":"Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety","volume":"56","author":"Purkins","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb9070","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.2217\/pgs.14.141","article-title":"Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole","volume":"15","author":"Rom\u00e1n","year":"2014","journal-title":"Pharmacogenomics."},{"key":"10.1016\/j.ejps.2019.105061_bb0185","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1365-2125.2004.02329.x","article-title":"Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes","volume":"59","author":"Saito","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb9080","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1023\/A:1011035007591","article-title":"CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects","volume":"18","author":"Sakai","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.105061_bb0190","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/FPC.0b013e32834d4962","article-title":"PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19","volume":"22","author":"Scott","year":"2012","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.ejps.2019.105061_bb9085","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1365-2125.2009.03534.x","article-title":"Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype","volume":"68","author":"Scholz","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb9090","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00228-010-0869-3","article-title":"Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism","volume":"66","author":"Shi","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb0195","first-page":"753","article-title":"Probing CYP2C19 and CYP3A4 activities in Chinese liver microsomes by quantification of 5-hydroxyomeprazole and omeprazole sulphone","volume":"21","author":"Shu","year":"2000","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejps.2019.105061_bb0200","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1124\/dmd.114.061523","article-title":"Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic model","volume":"43","author":"Steere","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.105061_bb0205","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: from bench to byte\u2014 an update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105061_bb9095","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/00498251003748095","article-title":"Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes","volume":"40","author":"Tu","year":"2010","journal-title":"Xenobiotica."},{"key":"10.1016\/j.ejps.2019.105061_bb9100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00228-006-0251-7","article-title":"Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations","volume":"63","author":"Uno","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb9105","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/0091270005275430","article-title":"Lack of significant effect of grapefruit juice on the pharmacokinetics of lansoprazole and its metabolites in subjects with different CYP2C19 genotypes","volume":"45","author":"Uno","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb9110","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00228-008-0574-7","article-title":"The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers","volume":"65","author":"Wang","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb9115","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/0091270008327537","article-title":"CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole","volume":"49","author":"Weiss","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb0210","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ijpharm.2013.06.034","article-title":"Profiling biopharmaceutical deciding properties of absorption of lansoprazole enteric-coated tablets using gastrointestinal simulation technology","volume":"453","author":"Wu","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2019.105061_bb0215","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s11095-013-1293-z","article-title":"Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: application to predict drug\/genetic interactions","volume":"31","author":"Wu","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.105061_bb0220","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3109\/13880200903300220","article-title":"The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects","volume":"48","author":"Xu","year":"2010","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.ejps.2019.105061_bb0225","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2125.2010.03656.x","article-title":"Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles","volume":"69","author":"Yamazaki","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb9120","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1177\/0091270004269015","article-title":"Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes","volume":"44","author":"Yasui-Furukori","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb9125","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00228-006-0189-9","article-title":"Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese","volume":"62","author":"Yasumori","year":"2006","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105061_bb9130","first-page":"986","article-title":"Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes","volume":"25","author":"Yu-rong","year":"2004","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejps.2019.105061_bb0230","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40262-014-0181-y","article-title":"A physiologically based pharmacokinetic model for voriconazole disposition predicts intestinal first-pass metabolism in children","volume":"53","author":"Zane","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2019.105061_bb0235","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105061_bb0240","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/00498254.2011.559556","article-title":"Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects","volume":"41","author":"Zhang","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejps.2019.105061_bb0245","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/cpt.905","article-title":"Predictive performance of physiologically based pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children","volume":"104","author":"Zhou","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105061_bb0250","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/cpt.1352","article-title":"Oncology therapy drugs in China, Japan, and the United States: pharmacokinetic characteristics, dose regimens, and development strategies","volume":"105","author":"Zhou","year":"2019","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809871930332X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809871930332X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T02:05:05Z","timestamp":1568426705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809871930332X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":75,"alternative-id":["S092809871930332X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105061","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modelling","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105061"}}